Buprenorphine Hydrochloride, 0.3mg/mL recall — Endo Usa, Inc. (Class II)
Endo Usa, Inc. is recorded by the U.S. Food and Drug Administration (FDA) as recalling Buprenorphine Hydrochloride, 0.3mg/mL — a Class II recall, initiated 2026-03-13 and posted to the FDA enforcement report on 2026-05-20, under recall number D-0527-2026. Status Ongoing, with no termination date on the record. The reason the FDA record carries is, verbatim: “Crystallization; identified as Buprenorphine free base”. From the product description, the form is injection, the strength given is 0.3mg/mL and it is marked Rx only. 1 National Drug Code number is printed in the record: 42023-179-05. Distribution is recorded as “USA Nationwide” — Nationwide (US), with the recalling firm on record in MI, United States. It is the only recall number the FDA has filed under event ID 98610. 68 days separate the firm's initiation date from the FDA's report date on this record. Values are reproduced from the linked openFDA report; regulatory information, not medical advice.
Regulatory snapshot
| Recall number | D-0527-2026 |
|---|---|
| FDA event ID | 98610 |
| Classification | Class II (intermediate regulatory tier) |
| Status | Ongoing |
| Recalling firm | Endo Usa, Inc. |
| Recall initiated | 2026-03-13 |
| Reported by FDA | 2026-05-20 |
| Report lag | 68 days from initiation to report |
| Distribution | USA Nationwide — Nationwide (US) |
| Firm location on record | MI, United States |
| Product description (source) | Buprenorphine Hydrochloride, Injection, 0.3mg/mL, 5x1 mL Single Dose Vials, Rx only, Manufactured for: Endo USA, Malvern, PA 19855, NDC 42023-179-05. |
Reason reported by FDA
Crystallization; identified as Buprenorphine free base
6 words from the enforcement report field reason_for_recall, reproduced without edit — the firm's own wording, not an assessment.
Product identifiers in this record
5 identifying values matched by exact pattern in the 20-word product description above; each is a literal substring of it.
| Product named | Buprenorphine Hydrochloride |
|---|---|
| Form | Injection |
| Strength | 0.3mg/mL |
| NDC | 42023-179-05 |
| Marketing category | Rx only |
| Manufactured for | Endo USA, Malvern |
Reported in the same month (2026-05)
48 enforcement reports carry a report date in 2026-05; these 8 are the Class II ones nearest this record.
| Recall record | Recall number | Recalling firm | FDA tier | Reported |
|---|---|---|---|---|
| Oasis Tears PF, 10mL | D-0525-2026 | Oasis Medical, Inc. | Class II | 2026-05-20 |
| Ascend Laboratories, 25 mg | D-0547-2026 | Ascend Laboratories, LLC | Class II | 2026-05-20 |
| DELFLEX, 1.5% | D-0512-2026 | Fresenius Medical Care Holdings, Inc. | Class II | 2026-05-13 |
| DELFLEX, 2.5% | D-0513-2026 | Fresenius Medical Care Holdings, Inc. | Class II | 2026-05-13 |
| Duloxetine Delayed-Release Capsules, 30 mg | D-0514-2026 | Ajanta Pharma Ltd. | Class II | 2026-05-13 |
| Duloxetine Delayed-Release Capsules, 60 mg | D-0515-2026 | Ajanta Pharma Ltd. | Class II | 2026-05-13 |
| Duloxetine Delayed-Release Capsules, 20 mg | D-0516-2026 | Ajanta Pharma Ltd. | Class II | 2026-05-13 |
| BD PurPrep, 8.3% | D-0517-2026 | Carefusion 213, LLC | Class II | 2026-05-13 |
Nearest Class II recalls by date
213 of 250 indexed records share the Class II tier; the 8 nearest to 2026-05-20 by report date are listed here.
| Recall record | Recall number | Recalling firm | Strength / form | Reported |
|---|---|---|---|---|
| BD PurPrep, 8.3% | D-0518-2026 | Carefusion 213, LLC | 8.3% · Solution | 2026-05-13 |
| Octreotide Acetate for Injectable Suspension, 30 mg | D-0519-2026 | Teva Pharmaceuticals Usa, Inc | 30 mg · Injectable Suspension | 2026-05-13 |
| Enalapril Maleate Tablets, 20 mg | D-0520-2026 | JB Chemicals And Pharmaceuticals Ltd | 20 mg · Tablets | 2026-05-13 |
| Duloxetine Delayed-Release Capsules USP, 60mg | D-0522-2026 | Breckenridge Pharmaceutical, Inc. | 60mg · Delayed-Release Capsules | 2026-05-13 |
| NAPROXEN ORAL SUSPENSION, 125 mg/5mL | D-0523-2026 | Acella Pharmaceuticals, LLC | 125 mg/5mL · Oral Suspension | 2026-05-13 |
| TPN bag (patient specific), 1660 mL | D-0524-2026 | Central Admixture Pharmacy Services, Inc (caps) Los Angeles | 1660 mL · Injection | 2026-05-13 |
| Atomoxetine Capsules HCL, 10 mg | D-0538-2026 | Safecor Health, LLC | 10 mg · Capsules | 2026-05-27 |
| Liraglutide Injection, 18 mg/3 mL | D-0541-2026 | Lupin Pharmaceuticals Inc. | 18 mg/3 mL · Injection | 2026-05-27 |
Reading this record
Class II is the FDA's own severity tier for the recall action — 213 of the 250 indexed records carry it — and it describes the agency's assessment of the action, not a risk statement about any individual. Match a package against 42023-179-05 at the FDA source to confirm it is covered.
Namespace context: the Class II index (213 records) and the recall hub (250 records, 118 FDA events); Endo Usa, Inc. (1 indexed records) aggregates this firm across datasets.
Coverage and limits of this record
This page reflects the openFDA enforcement report for D-0527-2026 as ingested on 2026-08-22, which can lag the live FDA record and omits detail held only in primary documents. It offers no clinical assessment, no advice about whether to use any product, and no substitute. For any health question consult a qualified healthcare professional.
Source & provenance
- Official source
- https://api.fda.gov/drug/enforcement.json?search=recall_number:%22D-0527-2026%22
- Source dataset
- openFDA Drug Enforcement API
- Publication date
- 2026-05-20
- Ingested
- 2026-08-22
- Record hash
93bff770466bb8d6
Verify every value against the official FDA source above. This site links to the regulator's record rather than replacing it.